• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

    0.2800 +0.0100 (+3.70%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 252,737
    Open 0.2800
    Bid (Size) 0.2800 (1,000)
    Ask (Size) 0.2850 (5,000)
    Prev. Close 0.2700
    Today's Range 0.2505 - 0.2849
    52wk Range 0.2740 - 39.75
    Shares Outstanding 15,859,280
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
    Clears Pathway for Execution of Future R&D Milestone Events such as the Phase 1b, FIH Study for PRP in up to 50 Advanced Cancer Patients with Solid Tumors, First Quarter, 2027 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
    Clears Pathway for Execution of Future R&D Milestone Events such as the Phase 1b, FIH Study for PRP in up to 50 Advanced Cancer Patients with Solid Tumors, First Quarter, 2027 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire

    Performance

    52-Week Range 99.3% below 52-week high
    0.2800
    0.2752W Low 39.7552W High
    1 Week 30.4% below 1-week high
    0.271W Low 0.401W High

    Propanc Biopharma, Inc. - Common Stock (PPCB) traded between $0.27 and $39.75 over the past 52 weeks and last traded at $0.28, 99.3% below its 52-week high. Over the past week it ranged between $0.27 and $0.40.

    Past 12 Months
    -18.1%
    -57.0%
    -80.7%
    -90.3%
    -98.0%
    -99.2%
    1W -$0.06
    1M -$0.37
    3M -$1.17
    6M -$2.62
    YTD -$14.01
    1Y -$34.47

    PPCB was -99.2% over the past year, -90.3% over six months, -98.0% year to date, -18.1% in the last week.

    12 Months vs Market
    PPCB
    -99.2%
    DIA
    +11.9%
    SPY
    +13.8%
    QQQ
    +16.3%
    IWM
    +13.3%

    Over the past 12 months PPCB returned -99.2% versus DIA (Dow) +11.9%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.3%.

    Volume & Liquidity 0.14× 3-mo avg
    Today 252,737 3-mo avg 1.8M
    1W
    530.8K
    1M
    337.9K
    3M
    1.8M
    6M
    2.8M
    YTD
    1.8M
    1Y
    1.5M

    PPCB most recently traded 252,737 shares against a 3-month average daily volume of 1.8M.

    More News

    Read More
    News headline image
    Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    Friday's session: top gainers and losers ↗
    Via Chartmill
    Top movers analysis one hour before the close of the markets on 2026-08-27: top gainers and losers in today's session. ↗
    Via Chartmill
    These stocks are the most active in today's session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    Thursday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    These stocks that are showing activity before the opening bell on Friday. ↗
    Via Chartmill

    Frequently Asked Questions

    Is Propanc Biopharma, Inc. - Common Stock publicly traded?
    Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.
    What exchange does Propanc Biopharma, Inc. - Common Stock trade on?
    Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?
    The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market
    What is the current price of Propanc Biopharma, Inc. - Common Stock?
    The current price of Propanc Biopharma, Inc. - Common Stock is 0.2800
    When was Propanc Biopharma, Inc. - Common Stock last traded?
    The last trade of Propanc Biopharma, Inc. - Common Stock was at 10/23/26 04:00 PM ET
    What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?
    The market capitalization of Propanc Biopharma, Inc. - Common Stock is 4.44M
    How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?
    Propanc Biopharma, Inc. - Common Stock has 4M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.